SACI-IO HR+
SACI-IO HR+: Phase II Trial of Sacituzumab Govitecan ± Pembrolizumab in HR+/HER2- Metastatic Breast Cancer

Released: June 04, 2024

Expiration: June 03, 2025

Activity

Progress
1
Course Completed